Latest On Oramed Pharmaceuticals Inc (ORMP):
About Oramed Pharmaceuticals Inc (ORMP):
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
General
- Name Oramed Pharmaceuticals Inc
- Symbol ORMP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:12
- Last Split Date2013-01-23
- Fiscal Year EndAugust
- IPO Date2006-04-21
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.oramed.com
Valuation
- Price/Sales (Trailing 12 Mt.) 80.17
- Price/Book (Most Recent Quarter) 10.23
- Enterprise Value Revenue 98.01
Financials
- Most Recent Quarter 2020-11-30
- Current Year EPS Estimate -$0.50
- Next Year EPS Estimate -$0.73
- Operating Margin -559%
- Return on Assets -26%
- Return on Equity -64%
- Revenue 2.71 million
- Earnings Per Share -$0.87
- Revenue Per Share $0.12
- Gross Profit 2.71 million
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 273.73 million
- EBITDA -15430000
- Analyst Target Price $16.83
- Book Value Per Share $1.19
Share Statistics
- Shares Outstanding 29.37 million
- Shares Float 24.41 million
- % Held by Insiders 1391%
- % Held by Institutions 14.5%
- Shares Short 1.74 million
- Shares Short Prior Month 1.82 million
- Short Ratio 1.87
- Short % of Float 7%
- Short % of Shares Outstanding 6%
Technicals
- Beta 1.79
- 52 Week High $11.71
- 52 Week Low $2.4
- 50 Day Moving Average 9.25
- 200 Day Moving Average 4.92
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Oramed Pharmaceuticals Inc (ORMP) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Oramed Pharmaceuticals Inc (ORMP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-11-30 | 2021-01-14 | $N/A | -$0.23 | -$0.19 | -18.99% |
2020-08-31 | 2020-11-24 | $681000 | -$0.10 | -$0.13 | 23.08% |
2020-05-31 | 2020-07-07 | $N/A | -$0.10 | -$0.20 | 50% |
2020-02-29 | 2020-04-06 | $674000 | -$0.21 | -$0.18 | -20% |
2019-11-30 | 2020-01-09 | $674000 | -$0.15 | -$0.25 | 38.78% |
2019-08-31 | 2019-11-27 | $681000 | -$0.13 | -$0.25 | 46.94% |
2019-05-31 | 2019-07-10 | $682000 | -$0.23 | -$0.24 | 4.17% |
2019-02-28 | 2019-04-10 | $666000 | -$0.21 | -$0.27 | 20.75% |
2018-11-30 | 2019-01-14 | $674000 | -$0.25 | -$0.20 | -28.21% |
2018-08-31 | 2018-11-28 | $617000 | -$0.18 | -$0.30 | 39.33% |
2018-05-31 | 2018-07-12 | $617000 | -$0.30 | -$0.27 | -12.49% |
2018-02-28 | 2018-04-09 | $604000 | -$0.20 | -$0.30 | 32.2% |
2017-11-30 | 2018-01-11 | $611000 | -$0.18 | -$0.21 | 14.29% |
2017-08-31 | 2017-11-29 | $3.07 million | -$0.20 | -$0.26 | 23.08% |
2017-05-31 | 2017-07-06 | $-617000 | -$0.15 | -$0.27 | 44.44% |
2017-02-28 | 2017-04-05 | $611000 | -$0.24 | -$0.19 | -26.32% |
2016-11-30 | 2017-01-11 | $-610000 | -$0.20 | -$0.12 | -66.67% |
2016-08-31 | 2016-11-25 | $353000 | -$0.37 | -$0.17 | -124.24% |
2016-05-31 | 2016-07-06 | $163000 | -$0.15 | -$0.19 | 20% |
2016-02-29 | 2016-04-06 | $125000 | -$0.14 | -$0.19 | 26.32% |
2015-11-30 | 2016-01-13 | $N/A | -$0.21 | -$0.19 | -10.53% |
2015-08-31 | 2015-11-25 | $N/A | -$0.19 | -$0.18 | -5.56% |
2015-05-31 | 2015-07-01 | $N/A | -$0.15 | -$0.18 | 16.67% |
2015-02-28 | 2015-04-03 | $N/A | -$0.15 | -$0.22 | 31.82% |
2014-11-30 | 2015-01-08 | $N/A | -$0.19 | -$0.21 | 9.52% |
2014-08-31 | 2014-11-14 | $N/A | -$0.17 | -$0.20 | 15% |
2014-05-31 | 2014-07-14 | $N/A | -$0.18 | -$0.15 | -20% |
2014-02-28 | 2014-04-10 | $N/A | -$0.12 | -$0.18 | 33.33% |
2013-11-30 | 2014-01-14 | $N/A | -$0.14 | -$0.16 | 12.5% |
2013-08-31 | 2013-10-30 | $N/A | -$0.11 | ||
2013-05-31 | 2013-07-31 | $N/A | -$0.17 | ||
2013-02-28 | 2013-02-28 | $N/A | -$0.17 | ||
2012-11-30 | 2012-11-30 | $N/A | -$0.14 | ||
2012-08-31 | 2012-08-31 | $-141143 | -$0.23 | ||
2012-05-31 | 2012-05-31 | $N/A | -$0.09 | ||
2012-02-29 | 2012-02-29 | $-43111 | -$0.17 | ||
2011-11-30 | 2011-11-30 | $N/A | -$0.08 | ||
2011-08-31 | 2011-08-31 | $N/A | -$0.14 | ||
2011-05-31 | 2011-05-31 | $N/A | $0.08 | ||
2011-02-28 | 2011-02-28 | $N/A | -$0.12 | ||
2010-11-30 | 2010-11-30 | $N/A | -$0.12 | ||
2010-08-31 | 2010-08-31 | -$0.25 | |||
2010-05-31 | 2010-05-31 | -$0.17 | |||
2010-02-28 | 2010-02-28 | -$0.08 | |||
2009-11-30 | 2009-11-30 | -$0.13 | |||
2009-08-31 | 2009-08-31 | -$0.08 | |||
2009-05-31 | 2009-05-31 | -$0.11 | |||
2009-02-28 | 2009-02-28 | -$0.14 | |||
2008-11-30 | 2008-11-30 | -$0.25 | |||
2008-08-31 | 2008-08-31 | $-0.00 | |||
2008-05-31 | 2008-05-31 | -$0.21 | |||
2008-02-29 | 2008-02-29 | -$0.09 | |||
2007-11-30 | 2007-11-30 | -$0.09 | |||
2007-08-31 | 2007-08-31 | -$0.72 | |||
2007-05-31 | 2007-05-31 | -$0.09 | |||
2007-02-28 | 2007-02-28 | -$0.10 | |||
2006-11-30 | 2006-11-30 | -$0.02 | |||
2006-08-31 | 2006-08-31 | -$0.08 | |||
2006-05-31 | 2006-05-31 | -$0.05 | |||
2006-02-28 | 2006-02-28 | $-0.00 | |||
2005-11-30 | 2005-11-30 | $-0.00 |
Oramed Pharmaceuticals Inc (ORMP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date | Nov 30 2020 | Aug 31 2020 | May 31 2020 | Feb 29 2020 | Nov 30 2019 |
---|---|---|---|---|---|
Research Development | N/A | 2.97 million | N/A | 3.32 million | 2.02 million |
Income Before Tax | N/A | -3 million | N/A | -3.69 million | -2.54 million |
Selling General Administrative | N/A | 730000 | N/A | 1.39 million | 1.08 million |
Gross Profit | N/A | 681000 | N/A | 674000 | 674000 |
Ebit | N/A | -3.26 million | N/A | -3.68 million | -2.43 million |
Operating Income | N/A | -3.02 million | N/A | -4.04 million | -2.43 million |
Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
Total Revenue | N/A | 681000 | N/A | 674000 | 674000 |
Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
Total Other Income Expense Net | N/A | -115000 | N/A | 182000 | -114000 |
Net Income From Continuing Operations | N/A | -3 million | N/A | -3.69 million | -2.54 million |
Net Income Applicable to Common Shares | -5.57 million | N/A | -2.28 million | N/A | -2.54 million |
Cash Flow:
Date | Aug 31 2020 | May 31 2020 | Feb 29 2020 | Nov 30 2019 | Aug 31 2019 |
---|---|---|---|---|---|
Investments | 10.96 million | N/A | 4.08 million | 2.83 million | 2.64 million |
Change to Liabilities | N/A | -1.7 million | N/A | -1.39 million | -589000 |
Total Cash Flow from Investing Activities | N/A | -13.24 million | N/A | 2.83 million | 2.64 million |
Net Borrowings | N/A | N/A | N/A | N/A | N/A |
Total Cash Flow from Financial Activities | 1.48 million | N/A | 2.32 million | 13000 | N/A |
Change to Operating Activities | N/A | 54000 | N/A | 428000 | -664000 |
Change in Cash | 9.98 million | N/A | 2.76 million | -158000 | -617000 |
Total Cash from Operating Activities | -2.46 million | -3.36 million | N/A | -3 million | -3.27 million |
Depreciation | 2000 | N/A | 2000 | N/A | 4000 |
Other Cash Flow from Investing Activities | N/A | -4000 | N/A | 3000 | -2000 |
Change to Inventory | N/A | N/A | N/A | N/A | N/A |
Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
Change to Net Income | N/A | 569000 | N/A | 508000 | 261000 |
Capital Expenditures | 79000 | N/A | N/A | 3000 | 1000 |
Balance Sheet:
Date | Nov 30 2020 | Aug 31 2020 | May 31 2020 | Feb 29 2020 | Nov 30 2019 |
---|---|---|---|---|---|
Total Liabailities | N/A | 11.75 million | N/A | 13.79 million | 13.98 million |
Total Stockholder Equity | N/A | 32.88 million | N/A | 16.09 million | 17.16 million |
Other Current Liabilities | 2.8 million | N/A | N/A | N/A | 2.7 million |
Total Assets | N/A | 44.63 million | N/A | 29.88 million | 31.14 million |
Common Stock | 286000 | N/A | 279000 | N/A | 209000 |
Other Current Assets | N/A | N/A | N/A | N/A | N/A |
Retained Earnings | -98.18 million | -92.61 million | -89.62 million | -87.33 million | -83.65 million |
Other Liabilities | 6.52 million | N/A | 7.85 million | N/A | 9.28 million |
Other Assets | 20000 | N/A | 19000 | N/A | 17000 |
Cash | N/A | 19.3 million | N/A | 5.93 million | 3.17 million |
Total Current Liabilities | 5.74 million | 4.54 million | N/A | 5.16 million | 4.64 million |
Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
Property, Plant & Equipment | 1.05 million | N/A | 111000 | N/A | 133000 |
Total Current Assets | 36.02 million | 40.51 million | N/A | 29.49 million | 30.74 million |
Long Term Investments | N/A | 3.93 million | N/A | 250000 | 250000 |
Net Tangible Assets | 28.21 million | N/A | 34.11 million | N/A | 17.16 million |
Short Term Investments | N/A | 9.54 million | N/A | 5.7 million | 26.96 million |
Long Term Debt | N/A | N/A | N/A | N/A | N/A |
Inventory | N/A | N/A | N/A | N/A | N/A |
Accounts Payable | 2.81 million | 594000 | N/A | 2.38 million | 1.8 million |
Oramed Pharmaceuticals Inc (ORMP) Chart:
Oramed Pharmaceuticals Inc (ORMP) News:
Below you will find a list of latest news for Oramed Pharmaceuticals Inc (ORMP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Oramed Pharmaceuticals Inc (ORMP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|---|---|---|---|---|---|---|---|---|
2024-04-19 | 2.5 | 0.35 | CALL | 0 | 3 | 588.08 | TRUE | 0 | 0 |
2024-04-19 | 5 | 0.05 | CALL | 0 | 235 | 0 | FALSE | 0 | 0 |
2024-04-19 | 7.5 | 0.05 | CALL | 0 | 114 | 0 | FALSE | 0 | 0 |
2024-04-19 | 2.5 | 0.15 | PUT | 0 | 21 | 0 | FALSE | 0 | 0 |
2024-04-19 | 5 | 0 | PUT | 0 | 0 | 483.94 | TRUE | 0 | 0 |
2024-04-19 | 7.5 | 0 | PUT | 0 | 0 | 545.75 | TRUE | 0 | 0 |
2024-05-17 | 2.5 | 0.65 | CALL | 0 | 81 | 423.23 | TRUE | 0 | 0 |
2024-05-17 | 5 | 0.19 | CALL | 0 | 1643 | 0 | FALSE | 0 | 0 |
2024-05-17 | 7.5 | 0.1 | CALL | 0 | 21 | 0 | FALSE | 0 | 0 |
2024-05-17 | 2.5 | 0.2 | PUT | 1 | 12 | 87.94 | FALSE | 0.2 | 0 |
2024-05-17 | 5 | 1.96 | PUT | 0 | 80 | 101.72 | TRUE | 0 | 0 |
2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 367.07 | TRUE | 0 | 0 |
2024-08-16 | 2.5 | 0.9 | CALL | 0 | 110 | 318.66 | TRUE | 0 | 0 |
2024-08-16 | 5 | 0.2 | CALL | 0 | 1890 | 90.28 | FALSE | 0 | 0 |
2024-08-16 | 7.5 | 0.25 | CALL | 0 | 106 | 0 | FALSE | 0 | 0 |
2024-08-16 | 2.5 | 0.35 | PUT | 0 | 4 | 280.5 | FALSE | 0 | 0 |
2024-08-16 | 5 | 1.94 | PUT | 0 | 3 | 170.38 | TRUE | 0 | 0 |
2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 167.74 | TRUE | 0 | 0 |
2024-11-15 | 2.5 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
2024-11-15 | 5 | 0 | CALL | 0 | 0 | 262.68 | FALSE | 0 | 0 |
2024-11-15 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
2024-11-15 | 2.5 | 0 | PUT | 0 | 0 | 217.63 | FALSE | 0 | 0 |
2024-11-15 | 5 | 0 | PUT | 0 | 0 | 96.53 | TRUE | 0 | 0 |
2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 182.99 | TRUE | 0 | 0 |
Latest ORMP Trades:
Date | Shares | Price |
---|---|---|
Jun 13, 2022 7:58 PM EST | 90 | $4.005 |
Jun 13, 2022 7:59 PM EST | 400 | $4 |
Jun 13, 2022 7:59 PM EST | 100 | $3.995 |
Jun 13, 2022 7:59 PM EST | 200 | $3.995 |
Jun 13, 2022 7:59 PM EST | 99 | $3.995 |
Oramed Pharmaceuticals Inc (ORMP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-06-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1176309/000121390020016305/0001213900-20-016305-index.htm |
2017-07-28 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1176309/000000000017026732/0000000000-17-026732-index.htm |
2020-02-04 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1176309/000000000020001091/0000000000-20-001091-index.htm |
2018-07-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000091957418004721/0000919574-18-004721-index.htm |
2017-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017007168/0001213900-17-007168-index.htm |
2017-07-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390017007202/0001213900-17-007202-index.htm |
2017-07-20 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1176309/000121390017007770/0001213900-17-007770-index.htm |
2017-07-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390017007808/0001213900-17-007808-index.htm |
2017-07-28 | PRER14A | Preliminary Proxy Soliciting materials | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008003/0001213900-17-008003-index.htm |
2017-08-01 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008089/0001213900-17-008089-index.htm |
2017-08-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008213/0001213900-17-008213-index.htm |
2017-08-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008214/0001213900-17-008214-index.htm |
2017-08-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008215/0001213900-17-008215-index.htm |
2017-08-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008889/0001213900-17-008889-index.htm |
2017-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008982/0001213900-17-008982-index.htm |
2017-08-28 | 424B7 | Prospectus [Rule 424(b)(7)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390017009231/0001213900-17-009231-index.htm |
2017-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390017009427/0001213900-17-009427-index.htm |
2017-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390017009429/0001213900-17-009429-index.htm |
2017-10-16 | 424B7 | Prospectus [Rule 424(b)(7)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390017010619/0001213900-17-010619-index.htm |
2017-10-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017010951/0001213900-17-010951-index.htm |
2017-11-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390017011195/0001213900-17-011195-index.htm |
2017-11-03 | 424B7 | Prospectus [Rule 424(b)(7)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390017011295/0001213900-17-011295-index.htm |
2017-11-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1176309/000121390017012754/0001213900-17-012754-index.htm |
2018-01-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390018000390/0001213900-18-000390-index.htm |
2018-02-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018001245/0001213900-18-001245-index.htm |
2018-02-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018001247/0001213900-18-001247-index.htm |
2018-02-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018001250/0001213900-18-001250-index.htm |
2018-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390018002084/0001213900-18-002084-index.htm |
2018-04-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390018004196/0001213900-18-004196-index.htm |
2018-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018004250/0001213900-18-004250-index.htm |
2018-05-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018005618/0001213900-18-005618-index.htm |
2018-07-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390018008780/0001213900-18-008780-index.htm |
2018-07-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390018008784/0001213900-18-008784-index.htm |
2018-07-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018009128/0001213900-18-009128-index.htm |
2018-07-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390018009132/0001213900-18-009132-index.htm |
2018-07-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1176309/000121390018009486/0001213900-18-009486-index.htm |
2018-07-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1176309/000121390018009488/0001213900-18-009488-index.htm |
2018-07-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1176309/000121390018009875/0001213900-18-009875-index.htm |
2018-08-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018010829/0001213900-18-010829-index.htm |
2018-08-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390018011939/0001213900-18-011939-index.htm |
2018-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390018012630/0001213900-18-012630-index.htm |
2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390018015178/0001213900-18-015178-index.htm |
2018-11-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390018016314/0001213900-18-016314-index.htm |
2018-11-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1176309/000121390018016666/0001213900-18-016666-index.htm |
2018-12-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390018017333/0001213900-18-017333-index.htm |
2019-01-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390019000691/0001213900-19-000691-index.htm |
2019-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019003333/0001213900-19-003333-index.htm |
2019-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019003334/0001213900-19-003334-index.htm |
2019-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019003337/0001213900-19-003337-index.htm |
2019-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019003338/0001213900-19-003338-index.htm |
2019-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019004051/0001213900-19-004051-index.htm |
2019-03-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019005120/0001213900-19-005120-index.htm |
2019-04-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390019006121/0001213900-19-006121-index.htm |
2019-04-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019006288/0001213900-19-006288-index.htm |
2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019006512/0001213900-19-006512-index.htm |
2019-04-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019006513/0001213900-19-006513-index.htm |
2019-05-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019009033/0001213900-19-009033-index.htm |
2019-06-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019010104/0001213900-19-010104-index.htm |
2019-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019011646/0001213900-19-011646-index.htm |
2019-07-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019011856/0001213900-19-011856-index.htm |
2019-07-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390019012456/0001213900-19-012456-index.htm |
2019-07-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019012780/0001213900-19-012780-index.htm |
2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm |
2019-07-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019013179/0001213900-19-013179-index.htm |
2019-07-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019013773/0001213900-19-013773-index.htm |
2019-08-06 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1176309/000121390019014679/0001213900-19-014679-index.htm |
2019-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019016472/0001213900-19-016472-index.htm |
2019-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019017287/0001213900-19-017287-index.htm |
2019-09-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390019017289/0001213900-19-017289-index.htm |
2019-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019017770/0001213900-19-017770-index.htm |
2019-09-16 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019018195/0001213900-19-018195-index.htm |
2019-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019018196/0001213900-19-018196-index.htm |
2019-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019018197/0001213900-19-018197-index.htm |
2019-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019018198/0001213900-19-018198-index.htm |
2019-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019018199/0001213900-19-018199-index.htm |
2019-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019018200/0001213900-19-018200-index.htm |
2019-10-23 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1176309/000121390019020923/0001213900-19-020923-index.htm |
2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019022717/0001213900-19-022717-index.htm |
2019-11-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/0001213900-19-024940-index.htm |
2019-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390019025444/0001213900-19-025444-index.htm |
2019-12-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390019025901/0001213900-19-025901-index.htm |
2020-01-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000631/0001213900-20-000631-index.htm |
2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000983/0001213900-20-000983-index.htm |
2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000984/0001213900-20-000984-index.htm |
2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000985/0001213900-20-000985-index.htm |
2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000988/0001213900-20-000988-index.htm |
2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000989/0001213900-20-000989-index.htm |
2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000991/0001213900-20-000991-index.htm |
2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1176309/000121390020000993/0001213900-20-000993-index.htm |
2020-01-31 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1176309/000121390020002261/0001213900-20-002261-index.htm |
2020-02-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1176309/000121390020002759/0001213900-20-002759-index.htm |
2020-02-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390020003130/0001213900-20-003130-index.htm |
2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000121390020003270/0001213900-20-003270-index.htm |
2020-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020004778/0001213900-20-004778-index.htm |
2020-02-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390020004816/0001213900-20-004816-index.htm |
2020-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020005018/0001213900-20-005018-index.htm |
2020-03-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390020005116/0001213900-20-005116-index.htm |
2020-04-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390020008653/0001213900-20-008653-index.htm |
2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020008913/0001213900-20-008913-index.htm |
2020-06-16 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1176309/000121390020015109/0001213900-20-015109-index.htm |
2020-06-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1176309/000121390020016305/0001213900-20-016305-index.htm |
2020-07-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1176309/000121390020016864/0001213900-20-016864-index.htm |
2020-07-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020017505/0001213900-20-017505-index.htm |
2020-08-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020020031/0001213900-20-020031-index.htm |
2020-08-11 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1176309/000121390020021429/0001213900-20-021429-index.htm |
2020-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020024016/0001213900-20-024016-index.htm |
2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020025857/0001213900-20-025857-index.htm |
2020-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020027361/0001213900-20-027361-index.htm |
2020-10-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1176309/000121390020032805/0001213900-20-032805-index.htm |
2018-07-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000138713118003118/0001387131-18-003118-index.htm |
2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000138713119001135/0001387131-19-001135-index.htm |
2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000138713120001660/0001387131-20-001660-index.htm |
2018-07-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000153561018000095/0001535610-18-000095-index.htm |
2019-01-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000153561019000041/0001535610-19-000041-index.htm |
2020-01-21 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1176309/000153561020000050/0001535610-20-000050-index.htm |
2020-02-10 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1176309/999999999520000309/9999999995-20-000309-index.htm |
2018-04-16 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1176309/999999999718004782/9999999997-18-004782-index.htm |
2020-05-01 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1176309/999999999720002359/9999999997-20-002359-index.htm |
2020-05-01 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1176309/999999999720002360/9999999997-20-002360-index.htm |
Oramed Pharmaceuticals Inc (ORMP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oramed Pharmaceuticals Inc (ORMP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1391%Institutional Ownership: 1450%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2018-08-09 | Aviad Friedman | Director | Buy | 500.00 | 4.82 | 2,410.00 | 10,191.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390018010829/0001213900-18-010829-index.htm |
2018-08-09 | Aviad Friedman | Director | Buy | 2,000.00 | 4.98 | 9,960.00 | 12,191.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390018010829/0001213900-18-010829-index.htm |
2017-08-17 | David Mark Slager | Director | Buy | 112,613.00 | 3.77 | 424,055.51 | 1,299,436.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008982/0001213900-17-008982-index.htm |
2017-10-31 | David Mark Slager | Director | Buy | 16,892.00 | 3.77 | 63,608.52 | 1,316,328.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390017011195/0001213900-17-011195-index.htm |
2017-08-02 | Xiaopeng Li | Director | Buy | 89,636.00 | 8.50 | 761,906.00 | 206,350.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008214/0001213900-17-008214-index.htm |
2017-08-15 | Leonard Sank | Director | Buy | 11,262.00 | 6.00 | 67,572.00 | 282,158.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008889/0001213900-17-008889-index.htm |
2017-10-23 | Leonard Sank | Director | Buy | 5,631.00 | 6.00 | 33,786.00 | 287,789.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390017010951/0001213900-17-010951-index.htm |
2017-10-23 | Leonard Sank | Director | Buy | 6,373.00 | 6.00 | 38,238.00 | 294,162.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390017010951/0001213900-17-010951-index.htm |
2019-07-11 | Leonard Sank | Director | Buy | 1,320.00 | 3.22 | 4,250.40 | 295,482.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390019012780/0001213900-19-012780-index.htm |
2019-07-16 | Leonard Sank | Director | Buy | 20,000.00 | 3.47 | 69,316.00 | 315,482.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm |
2019-07-17 | Leonard Sank | Director | Buy | 20,000.00 | 3.58 | 71,562.00 | 335,482.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm |
2019-07-17 | Leonard Sank | Director | Buy | 10,020.00 | 3.74 | 37,496.84 | 345,502.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm |
2019-07-18 | Leonard Sank | Director | Buy | 4,497.00 | 3.86 | 17,335.94 | 349,999.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm |
2019-09-09 | Leonard Sank | Director | Buy | 15,000.00 | 2.90 | 43,500.00 | 364,999.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390019017770/0001213900-19-017770-index.htm |
2019-09-09 | Leonard Sank | Director | Buy | 10,000.00 | 2.95 | 29,500.00 | 374,999.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390019017770/0001213900-19-017770-index.htm |
2017-08-02 | Miriam Kidron | Chief Scientific Officer | Sell | 89,636.00 | 8.50 | 761,906.00 | 75,000.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390017008213/0001213900-17-008213-index.htm |
2018-07-10 | NADAV KIDRON | President and CEO | Sell | 61.00 | 5.98 | 364.97 | 958,087.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390018009128/0001213900-18-009128-index.htm |
2018-07-11 | NADAV KIDRON | President and CEO | Buy | 122.00 | 5.92 | 722.18 | 958,209.00 | https://www.sec.gov/Archives/edgar/data/1176309/000121390018009128/0001213900-18-009128-index.htm |